GNH USA

USA — NDC

Emgality 120 mg/mL (Galcanezumab-Gnlm) Injection, solution

GNH USA supplies EMGALITY 120 mg/mL (Galcanezumab-Gnlm), a calcitonin gene-related peptide (CGRP) antagonist for the preventive treatment of migraine

Galcanezumab-Gnlm
Emgality
INJECTION, SOLUTION
120 mg/mL

Request sourcing

1
Pack/s

What is Galcanezumab-Gnlm?

Galcanezumab-gnlm, the active ingredient in EMGALITY 120 mg/mL, is a calcitonin gene-related peptide (CGRP) antagonist presented as a 120 mg/mL injection, solution for subcutaneous use. It is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache in adults.

GNH USA supplies EMGALITY 120 mg/mL as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

What is Galcanezumab-Gnlm used for?

EMGALITY 120 mg/mL is a calcitonin gene-related peptide (CGRP) antagonist used in the management of migraine and cluster headaches.

- Migraine: Preventive treatment to reduce the frequency and severity of migraine attacks. - Episodic Cluster Headache: Treatment to manage and reduce the frequency of cluster headache episodes. - Subcutaneous Use: Administered via injection for targeted therapeutic effects.

What are the side effects of Galcanezumab-Gnlm?

EMGALITY 120 mg/mL may cause various side effects, ranging from common to serious or rare.

Common Side Effects: - Injection site reactions, such as pain, redness, or swelling. - Nausea and vomiting. - Fatigue and dizziness. - Constipation. - Upper respiratory tract infection. - Hypersensitivity reactions, including rash or itching.

Serious or Rare Side Effects: - Serious hypersensitivity reactions, including anaphylaxis and angioedema. - Constipation with serious complications. - New-onset or worsening of pre-existing hypertension. - New-onset or worsening of pre-existing Raynaud's phenomenon. - Dyspnea and urticaria.

What precautions apply to Galcanezumab-Gnlm?

EMGALITY 120 mg/mL should be used with caution and under the supervision of a healthcare provider.

- Hypersensitivity: Discontinue use if serious hypersensitivity reactions occur. - Constipation: Monitor for signs of serious complications. - Hypertension: Regularly monitor blood pressure. - Raynaud's Phenomenon: Be aware of symptoms such as numbness, coolness, or color changes in fingers or toes. - Storage: Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

What does Galcanezumab-Gnlm interact with?

EMGALITY 120 mg/mL may interact with other medications, requiring careful monitoring or avoidance.

Major Interactions (Avoid): - None identified.

Moderate Interactions (Monitor Closely): - None identified.

Frequently asked questions

What is EMGALITY 120 mg/mL used for?+
EMGALITY 120 mg/mL is used for the preventive treatment of migraine and the treatment of episodic cluster headache in adults. It is a calcitonin gene-related peptide (CGRP) antagonist that helps reduce the frequency and severity of these conditions.
How does Galcanezumab-Gnlm work?+
Galcanezumab-gnlm is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand, blocking its binding to the receptor. This action is believed to reduce the frequency and severity of migraine and cluster headaches by modulating the activity of CGRP, a peptide involved in pain signaling and vascular dilation.
What is the usual dose of EMGALITY 120 mg/mL?+
The dosage of EMGALITY 120 mg/mL is determined by a healthcare provider based on the specific condition being treated. For migraine, the recommended dosage is a 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg. For episodic cluster headache, the recommended dosage is 300 mg (administered as three consecutive injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period.
Is EMGALITY 120 mg/mL safe during pregnancy or breastfeeding?+
The safety of EMGALITY 120 mg/mL during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider to discuss the potential risks and benefits before using this medication during pregnancy or while breastfeeding.
How do I order EMGALITY 120 mg/mL from GNH USA?+
To order EMGALITY 120 mg/mL from GNH USA, submit an enquiry on the product page at gnh-usa.com with the required quantity. GNH USA supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then reply with pricing, availability, shipping (including cold-chain where relevant), and the import paperwork.
How does EMGALITY 120 mg/mL compare to other migraine treatments?+
EMGALITY 120 mg/mL is a CGRP antagonist specifically developed for the preventive treatment of migraine. Compared to other migraine treatments, it offers a targeted approach by blocking the CGRP ligand, which is believed to play a key role in migraine pathogenesis. The choice of treatment depends on individual patient factors and should be discussed with a healthcare provider.
How should EMGALITY 120 mg/mL be stored and handled?+
EMGALITY 120 mg/mL should be stored refrigerated at 2-8°C (36-46°F) in the original carton to protect it from light. It should not be frozen or shaken. The medication may be stored out of refrigeration in the original carton at temperatures up to 30°C (86°F) for up to 7 days. Once stored out of refrigeration, it should not be placed back in the refrigerator. If these conditions are exceeded, the medication must be discarded.
How is EMGALITY 120 mg/mL administered?+
EMGALITY 120 mg/mL is administered subcutaneously. The injection can be given in the abdomen, thigh, back of the upper arm, or buttocks. It is important to follow the instructions provided by the healthcare provider or the product labeling for proper administration.
What are the most serious risks to watch for with EMGALITY 120 mg/mL?+
The most serious risks associated with EMGALITY 120 mg/mL include serious hypersensitivity reactions, such as anaphylaxis and angioedema, constipation with serious complications, new-onset or worsening of pre-existing hypertension, and new-onset or worsening of pre-existing Raynaud's phenomenon. Patients should be monitored for these potential adverse effects.
Who should not use EMGALITY 120 mg/mL?+
EMGALITY 120 mg/mL is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Patients should consult with their healthcare provider to determine if this medication is appropriate for them, considering their medical history and current medications.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Galcanezumab-Gnlm
Brand
Emgality
Strength
120 mg/mL
Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Pack size
2 SYRINGE in 1 CARTON (0002-1436-61) / 1 mL in 1 SYRINGE
Manufacturer
Eli Lilly and Company
Origin
USA

Related products

EMGALITY 120 mg/mL

EMGALITY 120 mg/mL

Galcanezumab-Gnlm · 120 mg/mL

Emgality
INJECTION, SOLUTION
Eli Lilly and Company
USA
EMGALITY 120 mg/mL

EMGALITY 120 mg/mL

Galcanezumab-Gnlm · 120 mg/mL

Emgality
INJECTION, SOLUTION
Eli Lilly and Company
USA
EMGALITY 100 mg/mL

EMGALITY 100 mg/mL

Galcanezumab-Gnlm · 100 mg/mL

Emgality
INJECTION, SOLUTION
Eli Lilly and Company
USA